Rigel Pharmaceuticals' Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults
Shots:
- The approval is based on three FIT studies results assessing Tavalisse (100/150mg- bid) vs Placebo in 150 patients with chronic ITP in ratio 2:1
- The FIT studies result: FIT-1 (NCT02076399) stable platelets response (SPR) (18% vs 0%); FIT-2 (NCT02076412) SPR (16% vs 4%); FIT-3 (23%)
- Tavalisse (fostamatinib disodium hexahydrate- PO) is a spleen tyrosine kinase (SYK) inhibitor and has received OD designation in Jan-2018
Ref: Rigel | Image: Glassdoor
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
